PATH is sponsoring a Phase 3 clinical study is to generate immunogenicity data for one dose of Innovax 9vHPV vaccine compared to a one dose of GARDASIL 9, with the prospect of providing evidence for another nine-valent vaccine product option for single-dose vaccination.